A PYMNTS Company

China: Johnson & Johnson rockets into China’s pharma market

By  |  November 10, 2014

Johnson & Johnson says it is looking to grow within China’s pharmaceuticals industry full-speed ahead and announced plans to new acquisitions in the market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say J&J’s sales in China last year saw a 10 percent increase from 2012, and the company is now running with its success. J&J CEO Alex Gorsky told reporters that the company now wants to acquire drug and consumer health brands in China to expand current partnerships with Chinese drug makers.

    Reports say J&J has placed one of its chairmen in charge of all operations in China to facilitate the company’s direction.

    The company added that it is not deterred by recent criticism against Chinese government officials accused of unfairly treating foreign companies. Johnson & Johnson was fined by Chinese competition officials for “monopolistic pricing” of its contact lens operations.

    Full content: Fierce Pharma

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.